MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock under the...
$24,857K
(14521.76%↑ Y/Y)
Proceeds from sales or
maturities of investments
$26,240K
(-17.74%↓ Y/Y)
Proceeds from exercise of
stock options
$320K
Proceeds from common
stock issuances under...
$143K
(-15.88%↓ Y/Y)
Net cash provided by
financing activities
$24,399K
(-66.56%↓ Y/Y)
Net cash provided by
(used in) investing...
$14,264K
(160.51%↑ Y/Y)
Canceled cashflow
$946K
Canceled cashflow
$11,976K
Net change in cash,
cash equivalents and...
$21,066K
(4459.74%↑ Y/Y)
Canceled cashflow
$17,597K
Offering costs incurred
and paid to third...
$804K
Payments on finance
leases
$142K
(-49.47%↓ Y/Y)
Stock based
compensation expense
$5,690K
(-15.93%↓ Y/Y)
Prepaid expenses and
other current assets
-$898K
(-135.00%↓ Y/Y)
Accounts payable
$828K
(-93.87%↓ Y/Y)
Accrued expenses and
other current...
$689K
(114.29%↑ Y/Y)
Reduction in the carrying
amount of rou assets,...
$402K
(-44.86%↓ Y/Y)
Reduction in the carrying
amount of rou assets,...
$80K
(-50.00%↓ Y/Y)
Depreciation and
amortization expense
$74K
(-39.34%↓ Y/Y)
Amortization of premium
(accretion of discount) on...
-$21K
(54.35%↑ Y/Y)
Purchases of investments
$11,969K
(-78.38%↓ Y/Y)
Purchase of property and
equipment
$7K
(-93.52%↓ Y/Y)
Net cash used in
operating activities
-$17,597K
(64.04%↑ Y/Y)
Canceled cashflow
$8,682K
Net loss
-$25,867K
(55.98%↑ Y/Y)
Lease liabilities,
operating
-$412K
(42.86%↑ Y/Y)
Back
Back
Cash Flow
Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. (LXEO)
source: myfinsight.com